Literature DB >> 25114763

Comparison of dexmedetomidine versus propofol for sedation in mechanically ventilated patients after cardiovascular surgery.

Matthew Wanat1, Kalliopi Fitousis2, Fariedeh Boston2, Faisal Masud3.   

Abstract

Many cardiovascular surgeries are fast-tracked to extubation and require short-term sedation. Dexmedetomidine and propofol have very different mechanisms of action and pharmacokinetic profiles that make them attractive sedative agents in this patient population. Recently, there has been increased use of dexmedetomidine in the intensive care unit (ICU), but few studies exist or have been published directly comparing both agents in this setting. We conducted a retrospective cohort study with patients admitted to the ICU after cardiovascular surgery from January through June 2011. Adult patients who underwent coronary artery bypass and/or cardiac valve surgery received either dexmedetomidine or propofol continuous infusion for short-term sedation after cardiovascular surgery. The primary end point was time (hours) on mechanical ventilation after surgery. Secondary end points included ICU length of stay (LOS), hospital LOS, incidence of delirium, and requirement of a second sedative agent. A total of 352 patients met study inclusion criteria, with 33 enrolled in the dexmedetomidine group and 319 in the propofol group. Time on mechanical ventilation was shorter in the dexmedetomidine group (7.4 hours vs. 12.9 hours, P = .042). No difference was seen in ICU or hospital LOS. The need for a second sedative agent to achieve optimal sedation (24% vs. 27%, P = .737) and incidence of delirium (9% vs. 7.5%, P = .747) were similar between both groups. Sedation with dexmedetomidine resulted in a significant reduction in time on mechanical ventilation. However, no difference was seen in ICU or hospital LOS, incidence of delirium, or mortality.

Entities:  

Keywords:  cardiovascular surgery; delirium; dexmedetomidine; propofol; sedation

Mesh:

Substances:

Year:  2014        PMID: 25114763      PMCID: PMC4117329          DOI: 10.14797/mdcj-10-2-111

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  31 in total

Review 1.  A systematic review of the safety and effectiveness of fast-track cardiac anesthesia.

Authors:  Paul S Myles; David J Daly; George Djaiani; Anna Lee; Davy C H Cheng
Journal:  Anesthesiology       Date:  2003-10       Impact factor: 7.892

2.  Protocolized and target-based sedation and analgesia in the ICU.

Authors:  Curtis N Sessler; Sammy Pedram
Journal:  Anesthesiol Clin       Date:  2011-12

3.  Acute pancreatitis induced by short-term propofol administration.

Authors:  Sven Gottschling; Reinhard Larsen; Sascha Meyer; Norbert Graf; Harald Reinhard
Journal:  Paediatr Anaesth       Date:  2005-11       Impact factor: 2.556

4.  Effect of a dexmedetomidine substitution during a nationwide propofol shortage in patients undergoing coronary artery bypass graft surgery.

Authors:  Marc G Reichert; Whitney A Jones; Roger L Royster; Thomas F Slaughter; Neal D Kon; Edward H Kincaid
Journal:  Pharmacotherapy       Date:  2011-07       Impact factor: 4.705

Review 5.  Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine.

Authors:  Paul M Szumita; Steven A Baroletti; Kevin E Anger; Michael E Wechsler
Journal:  Am J Health Syst Pharm       Date:  2007-01-01       Impact factor: 2.637

Review 6.  Propofol: therapeutic indications and side-effects.

Authors:  Paul E Marik
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

7.  Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.

Authors:  E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

8.  Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.

Authors:  Pratik P Pandharipande; Brenda T Pun; Daniel L Herr; Mervyn Maze; Timothy D Girard; Russell R Miller; Ayumi K Shintani; Jennifer L Thompson; James C Jackson; Stephen A Deppen; Renee A Stiles; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  JAMA       Date:  2007-12-12       Impact factor: 56.272

9.  ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens.

Authors:  Daniel L Herr; S T John Sum-Ping; Michael England
Journal:  J Cardiothorac Vasc Anesth       Date:  2003-10       Impact factor: 2.628

Review 10.  Propofol-related infusion syndrome in intensive care patients.

Authors:  Stephanie Mallow Corbett; Isaac D Montoya; Frederick A Moore
Journal:  Pharmacotherapy       Date:  2008-02       Impact factor: 4.705

View more
  5 in total

1.  Dexmedetomidine attenuates oxidative stress induced lung alveolar epithelial cell apoptosis in vitro.

Authors:  Jian Cui; Hailin Zhao; Chunyan Wang; James J Sun; Kaizhi Lu; Daqing Ma
Journal:  Oxid Med Cell Longev       Date:  2015-03-08       Impact factor: 6.543

2.  Sedation effects by dexmedetomidine versus propofol in decreasing duration of mechanical ventilation after open heart surgery.

Authors:  Ahmed Said Elgebaly; Mohab Sabry
Journal:  Ann Card Anaesth       Date:  2018 Jul-Sep

3.  Propofol infusion syndrome & COVID-19 in a victim of multiple gunshot wounds: Diagnostic and therapeutic dilemmas.

Authors:  Felicia H Lew; Kevin M Chang; Eduardo Smith Singares
Journal:  Trauma Case Rep       Date:  2022-08-01

4.  A new approach to the prevention and treatment of delirium in elderly patients in the intensive care unit.

Authors:  Andrew B Rosenzweig; Charmian D Sittambalam
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-09-01

5.  Comparison between Dexmedetomidine and Midazolam for Sedation in Patients with Intubation after Oral and Maxillofacial Surgery.

Authors:  Li Wang; Tiejun Zhang; Lili Huang; Wei Peng
Journal:  Biomed Res Int       Date:  2020-04-08       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.